PFE Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of -9.34% compared to Pfizer Inc.'s net margin of 27.55%. Pfizer Inc.'s return on equity of 10.84% beat Gilead Sciences, Inc.'s return on equity of 41.72%.

Pfizer Inc. has a consensus price target of $28.63, signalling upside risk potential of 3.8%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $151.12 which suggests that it could fall by -2.49%. Given that Pfizer Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Pfizer Inc. is more attractive than Gilead Sciences, Inc..

Pfizer Inc. has a beta of 0.472, which suggesting that the stock is 52.751% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.360, suggesting its less volatile than the S&P 500 by 63.985%.

Pfizer Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 6.24%. Gilead Sciences, Inc. offers a yield of 2.04% to investors and pays a quarterly dividend of $0.79 per share. Pfizer Inc. pays 126.47% of its earnings as a dividend. Gilead Sciences, Inc. pays out 46.61% of its earnings as a dividend. Gilead Sciences, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer Inc.'s is not.

Pfizer Inc. quarterly revenues are $17.6B, which are larger than Gilead Sciences, Inc. quarterly revenues of $7.9B. Pfizer Inc.'s net income of -$1.6B is lower than Gilead Sciences, Inc.'s net income of $2.2B. Notably, Pfizer Inc.'s price-to-earnings ratio is 20.35x while Gilead Sciences, Inc.'s PE ratio is 22.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer Inc. is 2.51x versus 6.61x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -9.34% compared to Pfizer Inc.'s net margin of 20.83%. Pfizer Inc.'s return on equity of 10.84% beat Johnson & Johnson's return on equity of 34.46%.

Pfizer Inc. has a consensus price target of $28.63, signalling upside risk potential of 3.8%. On the other hand Johnson & Johnson has an analysts' consensus of $231.25 which suggests that it could fall by -5.01%. Given that Pfizer Inc. has higher upside potential than Johnson & Johnson, analysts believe Pfizer Inc. is more attractive than Johnson & Johnson.

Pfizer Inc. has a beta of 0.472, which suggesting that the stock is 52.751% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

Pfizer Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 6.24%. Johnson & Johnson offers a yield of 2.11% to investors and pays a quarterly dividend of $1.30 per share. Pfizer Inc. pays 126.47% of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer Inc.'s is not.

Pfizer Inc. quarterly revenues are $17.6B, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Pfizer Inc.'s net income of -$1.6B is lower than Johnson & Johnson's net income of $5.1B. Notably, Pfizer Inc.'s price-to-earnings ratio is 20.35x while Johnson & Johnson's PE ratio is 22.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer Inc. is 2.51x versus 6.27x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -9.34% compared to Pfizer Inc.'s net margin of -19.69%. Pfizer Inc.'s return on equity of 10.84% beat Moderna, Inc.'s return on equity of -30.18%.

Pfizer Inc. has a consensus price target of $28.63, signalling upside risk potential of 3.8%. On the other hand Moderna, Inc. has an analysts' consensus of $39.00 which suggests that it could fall by -7.65%. Given that Pfizer Inc. has higher upside potential than Moderna, Inc., analysts believe Pfizer Inc. is more attractive than Moderna, Inc..

Pfizer Inc. has a beta of 0.472, which suggesting that the stock is 52.751% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

Pfizer Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 6.24%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer Inc. pays 126.47% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Pfizer Inc. quarterly revenues are $17.6B, which are larger than Moderna, Inc. quarterly revenues of $1B. Pfizer Inc.'s net income of -$1.6B is lower than Moderna, Inc.'s net income of -$200M. Notably, Pfizer Inc.'s price-to-earnings ratio is 20.35x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer Inc. is 2.51x versus 7.33x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -9.34% compared to Pfizer Inc.'s net margin of 21.74%. Pfizer Inc.'s return on equity of 10.84% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Pfizer Inc. has a consensus price target of $28.63, signalling upside risk potential of 3.8%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $868.04 which suggests that it could grow by 8.08%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Pfizer Inc..

Pfizer Inc. has a beta of 0.472, which suggesting that the stock is 52.751% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Pfizer Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 6.24%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.44% to investors and pays a quarterly dividend of $0.88 per share. Pfizer Inc. pays 126.47% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer Inc.'s is not.

Pfizer Inc. quarterly revenues are $17.6B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Pfizer Inc.'s net income of -$1.6B is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Pfizer Inc.'s price-to-earnings ratio is 20.35x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 19.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer Inc. is 2.51x versus 6.08x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.